DK314688A - Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf - Google Patents

Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf

Info

Publication number
DK314688A
DK314688A DK314688A DK314688A DK314688A DK 314688 A DK314688 A DK 314688A DK 314688 A DK314688 A DK 314688A DK 314688 A DK314688 A DK 314688A DK 314688 A DK314688 A DK 314688A
Authority
DK
Denmark
Prior art keywords
antibody
antibodies
fragments
hormones
peptide
Prior art date
Application number
DK314688A
Other languages
English (en)
Other versions
DK314688D0 (da
Inventor
Paul G Abrams
Robert W Schroff
Jr Alton C Morgan
Original Assignee
Neorx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp filed Critical Neorx Corp
Publication of DK314688D0 publication Critical patent/DK314688D0/da
Publication of DK314688A publication Critical patent/DK314688A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK314688A 1986-10-09 1988-06-09 Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf DK314688A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91717686A 1986-10-09 1986-10-09
PCT/US1987/002656 WO1988002594A2 (en) 1986-10-09 1987-10-09 Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof

Publications (2)

Publication Number Publication Date
DK314688D0 DK314688D0 (da) 1988-06-09
DK314688A true DK314688A (da) 1988-08-08

Family

ID=25438446

Family Applications (1)

Application Number Title Priority Date Filing Date
DK314688A DK314688A (da) 1986-10-09 1988-06-09 Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf

Country Status (8)

Country Link
EP (1) EP0288520B1 (da)
JP (1) JPH01501476A (da)
AT (1) ATE122894T1 (da)
AU (1) AU616161B2 (da)
CA (1) CA1340312C (da)
DE (1) DE3751319T2 (da)
DK (1) DK314688A (da)
WO (1) WO1988002594A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202252A (en) * 1982-03-05 1993-04-13 Houston Biotechnology Inc. Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
US5616122A (en) * 1986-11-04 1997-04-01 Baylor College Of Medicine Methods and compositions for preventing secondary cataracts
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US4986979A (en) * 1989-03-14 1991-01-22 Neorx Corporation Imaging tissue sites of inflammation
WO1991004755A1 (en) * 1989-09-29 1991-04-18 Neorx Corporation Methods for reducing non-target retention of immunoconjugates and metabolites thereof
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
WO1997017372A1 (en) * 1995-11-03 1997-05-15 The Binding Site Limited Production of antibodies, and medical uses involving antibodies
US9446146B2 (en) 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
US9011864B2 (en) 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
PL2242772T3 (pl) 2007-12-26 2015-05-29 Biotest Ag Immunokonjugaty nakierowane na CD138 i ich zastosowanie
ES2475201T3 (es) 2007-12-26 2014-07-10 Biotest Ag Agentes dirigidos contra CD138 y usos de los mismos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties

Also Published As

Publication number Publication date
WO1988002594A2 (en) 1988-04-21
AU8158787A (en) 1988-05-06
JPH01501476A (ja) 1989-05-25
EP0288520A1 (en) 1988-11-02
CA1340312C (en) 1999-01-12
AU616161B2 (en) 1991-10-24
DK314688D0 (da) 1988-06-09
ATE122894T1 (de) 1995-06-15
EP0288520B1 (en) 1995-05-24
DE3751319T2 (de) 1996-02-29
DE3751319D1 (de) 1995-06-29

Similar Documents

Publication Publication Date Title
DK314688D0 (da) Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf
AU563356B2 (en) Conjugate of enzyme and antibody
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
ES2112838T3 (es) Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
NL300418I1 (nl) Gebruik van trifunctionele bispecifieke en trispecifieke antilichamen voor de behandeling van maligne ascitis
EP0396387A3 (en) A novel antibody delivery system for biological response modifiers
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
WO1999063945A3 (en) Vaccination strategy to prevent and treat cancers
WO2002045653A3 (en) Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
DK0910407T3 (da) Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons
EP0354728A3 (en) Cytotoxic drug conjugates
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
ATE132197T1 (de) Monoklonale antikörper
EP0368668A3 (en) Antibody-drug conjugates
ES2144418T3 (es) Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario.
AU641736B2 (en) Delivery of agents
MY103231A (en) Immunoglobulin conjugates
DE60043070D1 (de) Proteine-abgabe durch polare epithelzellen schichte
McGuigan Binding of caerulein by antibodies to human gastrin I
Vogt et al. Functional identity of anaphylatoxin preparations obtained from different species and by different activation procedures. II. Immunological identity
ES8802263A1 (es) Procedimiento inmunologico para la determinacion de la hormona luteinizante
Mikalauskene et al. Preparation of monoclonal antibodies to gp51 antigen and their use for early diagnosis of bovine leukemia
Hochkeppel et al. Delivery of Interferons to Target Cells by Monoclonal Antibodies: Potential for the Specific Targeting of Other Lymphokines
TANNO Effect of moxibustion on blastoid transformation of rabbit peripheral lymphocytes

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment